N-acetylcysteine Prevents 4-hydroxynonenal- and Amyloid-beta-induced Modification and Inactivation of Neprilysin in SH-SY5Y Cells

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2010 Jan 12

PMID 20061637

Citations 9

Authors

Rui Wang

James S Malter

Deng-Shun Wang

Affiliations

Soon will be listed here.

Abstract

As one of the dominant amyloid-beta peptide (Abeta) proteases, neprilysin (NEP) plays a crucial role in maintaining a physiologic balance between Abeta production and catabolism. We have previously shown that NEP is modified by 4-hydroxynonenal (HNE) adducts, resulting in decreased activity in the brain of AD patients and cultured cells. In order to determine whether antioxidants can rescue NEP, SH-SY5Y cells were treated with HNE or Abeta, together with N-acetylcysteine for 24 hours, prior to analysis of NEP protein levels, activity, and oxidative modifications. Intracellular NEP developed HNE adducts after 24 hours of HNE or Abeta treatment as determined by immunoprecipitation, immunoblotting, and double immunofluorescence staining. N-acetylcysteine at 10 to 100 microM alleviated HNE adduction after HNE or Abeta treatment. In keeping with previous reports, HNE-modified NEP showed decreased catalytic activity. The present study demonstrates that antioxidants can be used to spare NEP from oxidative modification, suggesting a potential mechanism underlying the neuroprotective effects of antioxidants in aging or Alzheimer's disease.

Citing Articles

Effect of N-Acetyl Cysteine as an Adjuvant Treatment in Alzheimer's Disease.

Lomeli Martinez S, Pacheco Moises F, Bitzer-Quintero O, Ramirez-Jirano J, Delgado-Lara D, Cortes Trujillo I Brain Sci. 2025; 15(2).

PMID: 40002497 PMC: 11852533. DOI: 10.3390/brainsci15020164.

A Fundamental Role for Oxidants and Intracellular Calcium Signals in Alzheimer's Pathogenesis-And How a Comprehensive Antioxidant Strategy May Aid Prevention of This Disorder.

McCarty M, DiNicolantonio J, Lerner A Int J Mol Sci. 2021; 22(4).

PMID: 33669995 PMC: 7926325. DOI: 10.3390/ijms22042140.

Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?.

Kaufman M, Kanayama G, Hudson J, Pope Jr H Neurosci Biobehav Rev. 2019; 100:180-207.

PMID: 30817935 PMC: 6451684. DOI: 10.1016/j.neubiorev.2019.02.014.

The antioxidant xanthorrhizol prevents amyloid-β-induced oxidative modification and inactivation of neprilysin.

Lim C, Han J Biosci Rep. 2018; 38(1).

PMID: 29330223 PMC: 5794500. DOI: 10.1042/BSR20171611.

Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhou L, Liu J, Dong D, Wei C, Wang R Am J Transl Res. 2017; 9(1):184-196.

PMID: 28123645 PMC: 5250715.

References

Frautschy S, Yang F, Calderon L, Cole G . Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging. 1996; 17(2):311-21. DOI: 10.1016/0197-4580(95)02073-x. View

Aruoma O, Halliwell B, Hoey B, Butler J . The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989; 6(6):593-7. DOI: 10.1016/0891-5849(89)90066-x. View

Wang D, Lipton R, Katz M, Davies P, Buschke H, Kuslansky G . Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol. 2005; 64(5):378-85. DOI: 10.1093/jnen/64.5.378. View

Harvey B, Joubert C, du Preez J, Berk M . Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res. 2007; 33(3):508-17. DOI: 10.1007/s11064-007-9466-y. View

Shi Q, Gibson G . Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis Assoc Disord. 2007; 21(4):276-91. PMC: 3109432. DOI: 10.1097/WAD.0b013e31815721c3. View

Yankner B, Duffy L, Kirschner D . Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990; 250(4978):279-82. DOI: 10.1126/science.2218531. View

Wang D, Dickson D, Malter J . Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views. Int J Clin Exp Pathol. 2008; 1(1):5-18. PMC: 2480529. View

Forman M, Trojanowski J, Lee V . Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004; 10(10):1055-63. DOI: 10.1038/nm1113. View

Nunomura A, Chiba S, Lippa C, Cras P, Kalaria R, Takeda A . Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis. 2004; 17(1):108-13. DOI: 10.1016/j.nbd.2004.06.003. View

10.

Kowall N, McKee A, Yankner B, Beal M . In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol Aging. 1992; 13(5):537-42. DOI: 10.1016/0197-4580(92)90053-z. View

11.

Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B . Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci. 2004; 24(4):991-8. PMC: 6729819. DOI: 10.1523/JNEUROSCI.4792-03.2004. View

12.

Stanislaus R, Gilg A, Singh A, Singh I . N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats. J Autoimmune Dis. 2005; 2(1):4. PMC: 1097751. DOI: 10.1186/1740-2557-2-4. View

13.

Wang S, Simon B, Bennett D, Schneider J, Malter J, Wang D . The significance of Pin1 in the development of Alzheimer's disease. J Alzheimers Dis. 2007; 11(1):13-23. DOI: 10.3233/jad-2007-11105. View

14.

Shinall H, Song E, Hersh L . Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral. Biochemistry. 2005; 44(46):15345-50. DOI: 10.1021/bi050650l. View

15.

Iwata N, Tsubuki S, Takaki Y, SHIROTANI K, Lu B, Gerard N . Metabolic regulation of brain Abeta by neprilysin. Science. 2001; 292(5521):1550-2. DOI: 10.1126/science.1059946. View

16.

McKay A, Cassidy D, Sutherland F, Dixon E . Clinical results of N-acetylcysteine after major hepatic surgery: a review. J Hepatobiliary Pancreat Surg. 2008; 15(5):473-8. DOI: 10.1007/s00534-007-1306-6. View

17.

Wang D, Dickson D, Malter J . beta-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol. 2006; 2006(3):58406. PMC: 1559921. DOI: 10.1155/JBB/2006/58406. View

18.

Montine T, Amarnath V, Martin M, Strittmatter W, Graham D . E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol. 1996; 148(1):89-93. PMC: 1861611. View

19.

Caccamo A, Oddo S, Sugarman M, Akbari Y, LaFerla F . Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging. 2005; 26(5):645-54. DOI: 10.1016/j.neurobiolaging.2004.06.013. View

20.

Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido T . Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002; 70(3):493-500. DOI: 10.1002/jnr.10390. View